

2009 ANNUAL REVENUE: €6.7m

Further buoyant growth: +63%

Marseille, February 17 2010 - IPSOGEN (Alternext - FR0010626028 - ALIPS), a pioneer and key player in the development, manufacturing and marketing of molecular diagnostic tests for leukemia and breast cancer, today announces its consolidated revenue for the financial year to December 31 2009.

<i>In € thousands*</i>	Dec. 31 2009	Dec. 31 2008	Δ	Δ at constant forex
Revenue from Products	6,513	3,915	+66%	+63%
Revenue from Services	219	210	+4%	+4%
Total consolidated revenue	6,732	4,125	+63%	+60%

*audited data, IFRS

2009 revenue totaled €6.7 million, up 63% on the previous financial year and up 60% at constant forex. Revenue from Products, the most relevant indicator of the Group's development, increased by 66%, whilst revenue from Services remains marginal in line with IPSOGEN's strategy. Products activity thus represented 97% of total Group revenue last year, versus 95% in 2008. Revenue recorded by the Group, thanks to the JAK2 marker, jumped 119% compared to 2008.

Adjusted for non-recurrent items, notably upfronts associated with the signing of sub-license contracts with American laboratories, the growth in activity was very strong, with an increase of 48% between the second half of 2008 and the second half of 2009.

Sales in North America totaled €3.2m in 2009, versus €1.6m in 2008, giving growth of 98%. They thus represented 47% of consolidated revenue, versus 42% in 2008, making this region the Group's leading market. This buoyant increase lays witness to IPSOGEN's market share gains in the United States, notably via its flagship JAK2 test.

In Europe and Asia, revenue from Products continued to record significant growth for the seventh year in a row. They increased by 44% compared to the previous financial year, reflecting the Group's substantial growth potential, even on its historic market.

Vincent Fert, CEO of IPSOGEN, concludes: *"We have recorded a very promising financial year, in line with our expectations, that confirm 1) the value of our positioning in the leukemia molecular diagnosis market, on which we are becoming a benchmark player both in Europe and in the United States, 2) the strength of our business model, based on both direct and indirect sales, which provides a high recurrence of our sales. 2010 will be another key year for IPSOGEN, with the commercial launch of a new test in breast cancer. We are reiterating our guidance for further buoyant growth in activity."*



About IPSOGEN

IPSOGEN, Cancer Profiler, develops and markets molecular diagnostic tests that help map diseases in order to guide patients and oncologists' decisions along their therapeutic path. With more than 70 tests already used routinely worldwide for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, Ipsogen is now targeting breast cancer with the aim of providing as yet inaccessible diagnostic information.

Strengthened by its scientific, clinical and technological partnerships, and by its multidisciplinary team in France and the USA, IPSOGEN intends to become a world leader in the molecular profiling of cancers, and to pursue the development and promotion of diagnostic standards that have a significant impact on patients, medical professionals and society.

At December 31 2009, IPSOGEN employed 65 people. Its headquarters are located in Marseille, France.

The company has also a subsidiary, Ipsogen Inc., in Stamford, CT, USA.

For further information, visit www.ipsogen.com

Contacts

<p>IPSOGEN Vincent Fert President and CEO Tel.: +33 (0)4 9129 3090 fert@ipsogen.com</p>		<p>NewCap. Financial communication and Investor relations</p> <p>Axelle Vuillermet & Pierre Laurent Tel.: +33 (0)1 44 71 94 93 ipsogen@newcap.fr</p>
---	--	---